Novo Nordisk reported strong sales growth for its Wegovy and Ozempic drugs, while its 2025 guidance topped expectations. Shares in Novo, one of Europe's largest listed companies, rallied in the U.S.

Health-care companies rose after strong earnings from one major drug maker. Novo Nordisk shares rose sharply after the Danish obesity-drug maker posted fourth-quarter Ozempic sales of $4.71 billion, ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

A new study found that pa­tients tak­ing GLP-1s to treat type 2 di­a­betes have a low­er risk of de­vel­op­ing Alzheimer’s dis­ease, po­ten­tial­ly open­ing the door … ...

Novo Nordisk has announced topline results from the phase 3b trial STEP UP, which investigated the effects of two doses of Wegovy (semaglutide) in over 1,400 patients over the course of 72 weeks. Both ...

Bernard Arnault is once again in charge of Europe's most valuable company. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

Og det er blevet et problem, mener Caroline Hart Sehested, der er tidligere leder i Novo Nordisk og i dag indehaver af FutureTalent, der rådgiver virksomheder. Folk sidder med en følelse af, at de er ...

Novo Nordisk has commenced the STEP UP and STEP UP T2D trials to explore the efficacy of semaglutide 7.2mg. Credit: © 2025 Novo Nordisk A/S. Novo Nordisk’s high ...

SWAG - Secure Web Application Gateway (formerly known as letsencrypt, no relation to Let's Encrypt™) sets up an Nginx webserver and reverse proxy with php support and a built-in certbot client that ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other firms that took a hit on Friday. Wall Street’s main indices all finished in the green ...